EUCTR2018-002231-24-FR进行中（未招募）1 期
A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1 - NEXT-REGIRI
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 312
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Signed informed consent obtained before any study specific procedures
- •2.Male or female = 18 years of age
- •3.Histological or cytological documentation of adenocarcinoma of the colon or rectum
- •4.Patients with metastatic colorectal cancer
- •5.Progression during or within 3 months following the last administration of approved standard therapies, which must include a fluoropyrimidine (or raltitrexed), oxaliplatin, irinotecan, anti VEGF therapy and an anti EGFR therapy (for RAS wild-type tumors)
- •6.ECOG performance status =1
- •7.Life expectancy of at least 3 months
- •8.Patients with A/A CCND1 genotype of rs603965 CCND1
- •9.Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:Amylase and lipase =1.5 x ULN, Total bilirubin = 1.5 x ULN, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3.0 x ULN (= 5 x ULN for patients with liver involvement of their cancer), Alkaline phosphatase (ALP) = 2.5 x ULN (= 5.0 x ULN for patients with liver involvement for their cancer and/or have bone metastases), Platelet count = 100,000/mm3; Hemoglobin (Hb) = 9 g/dL; Absolute neutrophil count (ANC) = 1,500/ mm3. Transfusion to meet the inclusion criterion, Serum creatinine = 1.5 x ULN
- •10.International normalized ratio (INR) = 1.5 x ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) = 1.5 x ULN unless receiving treatment with therapeutic anticoagulation. Patients being treated with anticoagulant, e.g., heparin, will be allowed to participate provided no prior evidence of an underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care
- •11.Women of childbearing potential must have a blood or urine pregnancy test performed a maximum of 7 days before start of study treatment, and a negative result must be documented before start of study treatment
- •12.Women of childbearing potential and men must agree to use adequate contraception before entering the study until at least 8 weeks after the last study drug administration of Regorafenib and 12 weeks after the last study drug administration of Irinotecan. The investigator or a designated associate is requested to advise the patient on how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) as per standard of care.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 312
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 312
排除标准
- •1.Patients with A/G or G/G CCND1 genotype of rs603965 CCND1
- •2.Prior treatment with regorafenib or sorafenib
- •3.Prior treatment with TAS 102
- •4.Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug
- •5.Pregnant or breast-feeding subjects. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of study drug
- •6.Congestive heart failure = New York Heart Association (NYHA) class 2
- •7.Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
- •8.Myocardial infarction less than 6 months before start of study drug
- •9.Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
- •10.Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
- •11.Pleural effusion or ascites that causes respiratory compromise (= NCI-CTCAE V5.0 Grade 2 dyspnea)
- •12.Ongoing infection > Grade 2 NCI-CTCAE V5.0
- •13.Known history of human immunodeficiency virus (HIV) infection
- •14.Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
- •15.Patients with seizure disorder requiring medication
- •16.History of organ allograft
- •17.Patients with evidence or history of any bleeding diathesis, irrespective of severity
- •18.Any hemorrhage or bleeding event = NCI-CTC V5.0 Grade 3 within 4 weeks prior to the start of study medication
- •19.Non-healing wound, ulcer, or bone fracture
- •20.Dehydration NCI-CTCAE V5.0 Grade = 1
- •21.Substance abuse, medical, psychological or social conditions that may interfere with the subject’s participation in the study or evaluation of the study results
- •22.Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
- •23.Any illness or medical conditions that are unstable or could
- •jeopardize the safety of the subject and his/her compliance in the study
- •24.Persistent proteinuria of NCI-CTCAE V5.0 Grade 3 (> 3.5g/24 hours)
- •25.Patients unable to swallow oral medications
- •26.Any malabsorption condition
- •27.Chronic inflammatory bowel disease and / or bowel obstruction
- •28.Unresolved toxicity higher than NCI-CTCAE V.5.0 Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neurotoxicity = Grade 2
- •29.Concomitant participation or participation within the last 30 days in another clinical trial
- •30.Systemic anticancer therapy during this trial or within 4 weeks before randomization
研究者
相似试验
进行中（未招募）
1 期
Trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies.CTIS2024-512555-21-00Institut Regional Du Cancer De Montpellier78
进行中（未招募）
1 期
_Patients aged =18 years old with metastatic gastro-oesophageal adenocarcinomas after failure of a first-line fluoropyrimidine and platinum-based chemotherapies.EUCTR2018-002374-46-FRICANCER89
进行中（未招募）
不适用
maintenance therapy with regorafenibThe present proposal is aimed to evaluate the efficacy and safety of regorafenib as maintenance therapy in increasing the efficacy of the best available therapy for first line treatment fluoropirimidine based chemotherapy , any variant, in combination with either cetuximab or panitumumab) of RAS wild type metastatic colorectal cancer patients.MedDRA version: 17.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-005428-41-ESDepartment of experimental and clinical medicine F. Magrassi480
进行中（未招募）
不适用
maintenance therapy with regorafenibEUCTR2013-005428-41-DEDepartment of experimental and clincial medicine F. Magrassi480
已完成
不适用
Study of combined neoadjuvant chemotherapy and letrozol in Postmenopausal Women with locally advanced breast cancerBreast cancerACTRN12608000523303Shiraz University of Medical Sciences100